Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers

Thrombosis and Haemostasis

Volumn 103, Issue 5, 2010, Pages 926-935

  Schroecksnadel, Katharina ^a   Grammer, Tanja B ^b   Boehm, Bernhard O ^c   März, Winfried ^b,d,e   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b SYNLAB ACADEMY   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Coronary artery disease; CRP; Homocysteine; Inflammation; Neopterin

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FOLIC ACID; HOMOCYSTEINE; NEOPTERIN; VITAMIN B GROUP; AUTACOID; BIOLOGICAL MARKER; CYANOCOBALAMIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIBIOTIC THERAPY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE CLEARANCE; FEMALE; HEART FUNCTION; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN METABOLISM; SMOKING; STENOSIS; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION; BLOOD; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; CREATININE; DISEASE PROGRESSION; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEOPTERIN; VITAMIN B 12;

EID: 77952026024     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-07-0422     Document Type: Article

References (48)

1. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-1057.
2. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389.
3. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-413.
4. Harker LA, Slichter SJ, Scott CR, et al. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-543.
5. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3:1646-1654.
6. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
7. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
8. Falk E. Morphological features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63: 114E-120E.
9. Nathan CF, Murray HW, Wiebe ME, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-689.
10. Fuchs D, Weiss G, Reibnegger G, et al. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307-341. (Pubitemid 23011151)
11. Garcia-Moll X, Coccolo F, Cole D, et al. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000; 35: 956-962. (Pubitemid 30189928)
12. Auer J, Berent R, Labetanig E, et al. Serum neopterin and activity of coronary artery disease. Heart Dis 2001; 3: 297-301. (Pubitemid 33136297)
13. Adachi T, Naruko T, Itoh A, et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart 2007; 93: 1537-1541.
14. Ray KK, Morrow DA, Sabatine MS, et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115: 3071-3078.
15. Avanzas P, Arroyo-Espliguero R, Quiles J, et al. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 457-463. (Pubitemid 40314761)
16. Konstantino Y, Wolk R, Terra SG, et al. Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ? Acute Card Care 2007; 9: 197-206. (Pubitemid 350145786)
17. van Haelst PL, Liem A, van Boven AJ, et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non- Q-wave myocardial infarction. Am J Cardiol 2003; 92: 1201-1203. (Pubitemid 37377833)
18. Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110: 1747-1753.
19. Shah SH, Newby LK.C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 2003; 11: 169-179.
20. Zakai NA, Katz R, Jenny NS, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 2007; 5: 1128-1135.
21. Grammer TB, Fuchs D, Böhm BO, et al. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 2009; 55: 115-146.
22. Schroecksnadel K, Frick B, Kaser S, et al. Moderate hyperhomocysteinaemia and immune activation in patients with rheumatoid arthritis. Clin Chim Acta 2003; 338: 157-164.
23. Schroecksnadel K, Leblhuber F, Frick B, et al. Association of hyperhomocysteinemia in Alzheimer disease with elevated neopterin levels. Alzheimer Dis Assoc Disord 2004; 18: 129-133.
24. Frick B, Rudzite V, Schroecksnadel K, et al. Homocysteine, B vitamins and immune activation in coronary heart disease. Pteridines 2003; 14: 82-87.
25. Schroecksnadel K, Frick B, Wirleitner B, et al. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003; 134: 53-56.
26. Winkelmann BR, Maerz W, Boehm BO, et al. Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001; 2: S1-73.
27. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51: 5-40.
28. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999; 131: 331-339.
29. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72: 315-323.
30. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
31. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588.
32. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7 (Suppl 1): 332-339.
33. Fuchs D, Jaeger M, Widner B, et al. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Lab Med 2001; 39: 691-694.
34. Murr C, Fuith LC, Widner B, et al. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res 1999; 19: 1721-1728.
35. Solichova D, Melichar B, Svobodova I, et al. Fluorescence analysis of antioxidant vitamins and neopterin in nonagenarians. Biomed Chromatogr 1999; 13: 117-118. (Pubitemid 129544556)
36. Murr C, Schroecksnadel K, Winklhofer-Roob BM, et al. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009; 202: 543-549.
37. Cirillo P, Pacileo M, De Rosa S, et al. Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemost 2006; 4: 2248-2255.
38. Voutilainen S, Virtanen JK, Rissanen TH, et al. Serum folate and homocysteine and the incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 2004; 80: 317-323. (Pubitemid 41080004)
39. Bleie O, Semb AG, Grundt H, et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 2007; 262: 244-253. (Pubitemid 47087627)
40. Frick B, Gruber B, Schroecksnadel K, et al. Homocysteine but not neopterin declines in demented patients on B vitamins. J Neural Transm 2006; 113: 1815-1819. (Pubitemid 44657678)
41. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 1995; 274: 1526-1533.
42. de Bree A, Verschuren WM, Kromhout D, et al. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54: 599-618. (Pubitemid 35351198)
43. Ohsawa M, Okayama A, Nakamura M, et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med 2005; 41: 651-656. (Pubitemid 40732383)
44. O'Callaghan P, Meleady R, Fitzgerald T, et al. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580-1586.
45. Diamondstone LS, Tollerud DJ, Fuchs D, et al. Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population. J Clin Immunol 1994; 14: 368-374.
46. Schennach H, Murr C, Larcher C, et al. Neopterin concentrations in cord blood: a single-cohort study of paired samples from 541 pregnant women and their newborns. Clin Chem 2002; 48: 2059-2061. (Pubitemid 35222770)
47. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 6: 422-428.
48. Gueant-Rodriguez RM, Juilliere Y, Nippert M, et al. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. J Thromb Haemost 2007; 5: 1209-1216.